These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 9266415)

  • 21. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective.
    Hornykiewicz O
    Clin Neurol Neurosurg; 1992; 94 Suppl():S9-11. PubMed ID: 1320533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
    Duda J; Pötschke C; Liss B
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does oxidative stress participate in nerve cell death in Parkinson's disease?
    Hirsch EC
    Eur Neurol; 1993; 33 Suppl 1():52-9. PubMed ID: 8375433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed cell death: does it play a role in Parkinson's disease?
    Burke RE; Kholodilov NG
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S126-33. PubMed ID: 9749584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
    Isacson O; Bjorklund LM; Schumacher JM
    Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell death mechanisms in Parkinson's disease.
    Jellinger KA
    J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease.
    Barzilai A; Melamed E
    Trends Mol Med; 2003 Mar; 9(3):126-32. PubMed ID: 12657434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell death caused by the synergistic effects of zinc and dopamine is mediated by a stress sensor gene Gadd45b - implication in the pathogenesis of Parkinson's disease.
    Yang TC; Wu PC; Chung IF; Jiang JH; Fann MJ; Kao LS
    J Neurochem; 2016 Oct; 139(1):120-33. PubMed ID: 27385273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current views on the mechanisms of dopaminergic neuron death of the nigrostriatal system in Parkinson's disease].
    Bertrand E; Lechowicz W; Szpak GM; Dymecki J
    Neurol Neurochir Pol; 1997; 31(2):295-302. PubMed ID: 9380259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor.
    Nakao N; Yokote H; Nakai K; Itakura T
    J Neurosurg; 2000 Apr; 92(4):659-70. PubMed ID: 10761657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
    Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic neurons protected from degeneration by GDNF gene therapy.
    Choi-Lundberg DL; Lin Q; Chang YN; Chiang YL; Hay CM; Mohajeri H; Davidson BL; Bohn MC
    Science; 1997 Feb; 275(5301):838-41. PubMed ID: 9012352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease?
    Ziv I; Barzilai A; Offen D; Stein R; Achiron A; Melamed E
    Adv Neurol; 1996; 69():229-33. PubMed ID: 8615132
    [No Abstract]   [Full Text] [Related]  

  • 37. Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.
    Lopes FM; Bristot IJ; da Motta LL; Parsons RB; Klamt F
    Neuromolecular Med; 2017 Sep; 19(2-3):241-255. PubMed ID: 28721669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.
    Benskey MJ; Manfredsson FP; Lookingland KJ; Goudreau JL
    Neurotoxicology; 2015 Jan; 46():1-11. PubMed ID: 25447324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.